ArticleAmerican journal of translational research2016
Ginsenoside Rh2 alleviates tumor-associated depression in a mouse model of colorectal carcinoma.
Article in American journal of translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Ginsenosides in the management of depression: a comprehensive pharmacological review.Chinese medicine · 2026Review
- Ginsenoside Rh2 Protects Against Glutamate-Induced Neurotoxicity in PC12 Cells via Activation of the VEGF-mediated PI3K/Akt/mTOR Signaling Pathway.Neurochemical research · 2026Article
- Ginsenoside RhInternational journal of molecular sciences · 2024Article
- Therapeutic potential and possible mechanisms of ginseng for depression associated with COVID-19.Inflammopharmacology · 2024Review
- Mangiferin inhibits chronic stress-induced tumor growth in colorectal liver metastases via WAVE2 signaling pathway.Heliyon · 2023Article
- Transcriptome Analysis of the Anti-Proliferative Effects of Ginsenoside Rh3 on HCT116 Colorectal Cancer Cells.Molecules (Basel, Switzerland) · 2022Article
- Ginsenoside Rh2 administration produces crucial antidepressant-like effects in a CUMS-induced mice model of depression.Brain and behavior · 2022Article
- Forkhead Box q1 promotes invasion and metastasis in colorectal cancer by activating the epidermal growth factor receptor pathway.World journal of gastroenterology · 2022Article
- Ginsenoside Rh2 reduces depression in offspring of mice with maternal toxoplasma infection during pregnancy by inhibiting microglial activation via the HMGB1/TLR4/NF-κB signaling pathway.Journal of ginseng research · 2022Article
- Antidepressant Active Ingredients From Chinese Traditional HerbFrontiers in pharmacology · 2022Review
- The effect of ginsenosides on depression in preclinical studies: A systematic review and meta-analysis.Journal of ginseng research · 2021Article
- Network Pharmacology Interpretation of Fuzheng-Jiedu Decoction against Colorectal Cancer.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Paroxetine combined with fluorouracil plays a therapeutic role in mouse models of colorectal cancer with depression through inhibiting IL-22 expression to regulate the MAPK signaling pathway.Experimental and therapeutic medicine · 2020Article
- 20(S)-ginsenoside Rh2 as agent for the treatment of LMN-CRC via regulating epithelial-mesenchymal transition.Bioscience reports · 2020Article
- An Integrative Pharmacology-Based Pattern to Uncover the Pharmacological Mechanism of Ginsenoside H Dripping Pills in the Treatment of Depression.Frontiers in pharmacology · 2020Article
- Article
- FOXQ1 promotes cancer metastasis by PI3K/AKT signaling regulation in colorectal carcinoma.American journal of translational research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies reported remarkable high incidence of depression in cancer patients compared with the general population. Colorectal carcinoma (CRC) is one of the most frequent malignancies worldwide and has been found to be one of the malignancies with the highest incidence of patient depression. Thus, strategies that may alleviate CRC-associated depression may significantly improve the patients' life quality and outcome of the therapy. Ginsenoside Rh2 (GRh2) has been reported to have therapeutic effects on various diseases. However, whether it may also play a potential role in alleviating tumor-associated depression in CRC patients is unknown. Here, we studied the role of GRh2 in the control of depression in CRC using a mouse model. CRC was induced in mice through orthotopic implantation. GRh2 or control vehicle was then given to the mice twice per week for 4 weeks, after which the mice were subjected to a forced swim test (FST), a tail suspension test (TST) and a sucrose intake test (SIT). We found that the mice that received GRh2 treatment significantly improved their behaviors in all FST, TST and SIT tests, seemingly through decreases in the depression-associated cytokines, interleukin 6 (IL-6), IL-18 and tumor necrosis factor-alpha. Moreover, GRh2 significantly increased survival time of the CRC-mice. Together, our data suggest that GRh2 may alleviate tumor-associated depression in mice carrying CRC and highlight GRh2 treatment as a potential beneficial therapy for CRC-associated depression in patients.
Indexed as
Identifiers
27347326PMC4891431W2472190903What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.